Neuroendocrine differentiation of localized prostate cancer during endocrine therapy

Scandinavian Journal of Urology and Nephrology

Volumn 41, Issue 6, 2007, Pages 558-560

  Nemoto, Kaoru ^a,b   Tomita, Yuji ^b  

^a National Hospital Organization Hakodate Hospital   (Japan)

^b Kitamurayama Public Hospital   (Japan)

Author keywords

Endocrine therapy; Neuroendocrine differentiation; Prostate cancer

Indexed keywords

BICALUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CASE REPORT; CELL DIFFERENTIATION; GLEASON SCORE; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MALE; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADENOCARCINOMA; AGED; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIFFERENTIATION; GOSERELIN; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 36749000557     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590701365404     Document Type: Article

References (7)

1. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-55.
2. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, Di Silverio F. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 2006;60:462-70.
3. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000;38:250-4.
4. Renshaw AA, Granter SR. Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration. Diagn Cytopathol 2000;23:199-201.
5. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, et al. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001;8:431-6.
6. Hvamstad T, Jordal A, Hekmat N, Paus E, Fossa SD. Neuroendocrine serum tumor markers in hormone-resistant prostate cancer. Eur Urol 2003;44:215-21.
7. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003;55:168-79.